[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stroke-cva-or-transient-ischemic-attack\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stroke-cva-or-transient-ischemic-attack":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,77,99,131,163,192,216],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100625165","trunk-impairment-scale---adaptation-and-validation-in-french-100625165",false,"NCT07419087","Trunk Impairment Scale - Adaptation and Validation in French","KER-TIS fr","Inclusion criteria (Phase 1):\n\n* Patients over 18 years of age\n* Patients who have had a stroke\n* Full understanding of the French language\n* No cognitive disorders\n* No prior exposure to the TIS scale\n* Covered by a social security system\n* Having been informed, having agreed to participate in the study, and having signed the free and informed consent form.\n\nInclusion criteria (Phase 2):\n\n* Patients aged over 18 and under 85 years\n* Having had a stroke, with no time-since-onset limitation\n* Able to sit for 10 seconds without hand support\n* Able to provide informed consent\n* With an NIHSS score between 2 and 26\n* Covered by a social security system\n* Having been informed, having agreed to participate in the study, and having signed the free and informed consent form\n\nExclusion Criteria (Phase 1):\n\n* Insufficient command of the French language\n* Inability to understand instructions\n* Persons deprived of liberty (by judicial or administrative decision)\n* Adults under legal protection or unable to express their consent\n* Pregnant or breastfeeding women\n\nExclusion Criteria (Phase 2):\n\n* Contraindication to the sitting position or to hip adduction (hip prosthesis)\n* History of orthopedic or neurological disorders affecting sitting balance\n* Insufficient command of the French language\n* Inability to understand instructions\n* Person deprived of liberty (by judicial or administrative decision)\n* Adult under legal protection or unable to express consent\n* Pregnant or breastfeeding woman","ALL","18 Years","85 Years",{"count":20,"type":21},67,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of this project is to verify the validity and determine the clinimetric properties after translation and adaptation into French of the Trunk Impairment Scale (TIS), a scale for measuring trunk control and seated balance.",[27,28],"Stroke (CVA) or Transient Ischemic Attack","Stroke (CVA) or TIA",[30,31,32,33],"traduction","Trunk Impairment Scale","TIS","post-stroke","RECRUITING","2026-06-22",{"date":37,"type":38},"2026-06-24","ACTUAL",{"date":40,"type":38},"2026-03-19",{"date":42,"type":21},"2028-07-19",{"name":44,"class":45},"Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles de Kerpape","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100638954","optimized-recruitment-to-drive-equitable-research-in-stroke-empowering-decision-making-ordered-100638954","NCT07576647","Optimized Recruitment to Drive Equitable Research in Stroke, Empowering Decision-making (ORDERed)","ORDERed","Participants eligible for StrokeGoRed hospitalized cohort are eligible for ORDERed:\n\nInclusion Criteria:\n\n* All patients, regardless of age or baseline disability, seen in urgent TIA\u002Fstroke clinics and referred from the emergency department for suspected TIA or minor stroke will be included over one calendar year\n\nExclusion Criteria:\n\n* There are no exclusion criteria\n\nParticipants eligible for StrokeGoRed hospitalized cohort are eligible for ORDERed:\n\nInclusion Criteria:\n\n* Ischemic stroke\n* Intracerebral hemorrhage\n\nExclusion Criteria:\n\n* Cerebral venous thrombosis\n* Subarachnoid hemorrhage\n* Subdural hemorrhage\n* Intracranial hemorrhage due to trauma or underlying mass\n* Clinical transient ischemic attack without evidence of infarct on neuroimaging\n* Imaging abnormality (e.g., dissection, carotid stenosis, vessel irregularity) without imaging or clinical evidence of stroke\n* Stroke that occurred while being admitted for another reason\n* Stroke that started more than 14 days prior to admission\n* Stroke initially treated outside of Canada\n* Stroke where inpatient stroke or neurology service was not consulted",{"count":55,"type":21},1600,[24],"Stroke is a major health issue, especially for women, who are more likely than men to have worse outcomes and lower quality of life after a stroke. Yet, women are under-represented in stroke research, which limits how well treatments work for them. This study aims to change that by testing a new way to recruit women into stroke research using the ORDER toolkit, a set of easy-to-understand, women-focused materials like brochures and videos co-designed with patients. This new approach will be compared to the usual way of recruiting patients. The study will track how many people join, how long it takes to make a decision, and what influences participation. Patients and research coordinators will also share their feedback on the process. Our goal is to make stroke studies more inclusive so that research findings benefit everyone equally.",[59,27],"Stroke",[61,62,63,64,65],"Stroke rehabilitation","Clinical Trial","Informed consent","Diversity, Equity, Inclusion","Sex","NOT_YET_RECRUITING","2026-04-30",{"date":69,"type":38},"2026-05-08",{"date":71,"type":21},"2026-04",{"date":73,"type":21},"2029-08",{"name":75,"class":45},"McMaster University",3,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":46},"100617491","evaluating-the-effect-of-nurse-led-stroke-transitional-care-in-tanzania-100617491","NCT07319312","Evaluating the Effect of Nurse-Led Stroke Transitional Care in Tanzania","Evaluating the Clinical Effectiveness and Implementation Outcomes of Nurse-Led Stroke Transitional Care Model in Tanzania","Inclusion criteria\n\n* Clinical nurses and physicians with six months of working experience in stroke care\n* Clinical nurses and physicians with a minimum of diploma in their professions.\n* Stroke survivors with 18 years old and above\n* Stroke survivors admitted in the stroke units\n* Stroke survivors with primary diagnosis of stroke confirmed by brain CT\u002FMRI\n* Stroke survivors who undergo usual discharge process\n* Stroke survivors who live with their family caregivers\n* Stroke survivors who have mobile phones\n* Stroke survivors who can read and write\n* Stroke survivors who are able to communicate\n* Stroke survivors with National Institutes of Health Stroke Scale (NIHSS) \\\u003C 6\n* Stroke survivors with Modified Barthel Index (MBI) \\> 9\n* Stroke survivors with Modified Rankin Scale (mRS) \\\u003C 5\n* Stroke survivors with Montreal Cognitive Assessment Test (MoCA) \\> 14\n* Stroke survivors who are expected to stay in the ward for 3-5 days,\n* Stroke survivors who are expected to survive for 3 months\n* Family caregivers with mobile phones\n* Family caregivers who can read and write\n* Family caregivers who are able to communicate\n* Family caregivers who live with the patient after stroke\n\nExclusion criteria\n\n* Healthcare providers who will be on leave during the study period.\n* Stroke survivors with previous stroke who are not admitted in stroke units\n* Stroke survivors who are discharged against medical advice\n* Stroke survivors who have end-stage organ failure\n* Stroke survivors who have family caregivers\n* Stroke survivors who can't read\u002Fwrite\n* Stroke survivors who have no mobile phones.\n* Family caregivers without mobile phone that is accessible",{"count":85,"type":21},130,"OBSERVATIONAL","The goal of this observational study is to assess the effects of nurse-led stroke transitional care in stroke survivors, caregivers and healthcare providers who participate in nurse-led stroke transitional care program to improve discharge preparedness, disease self-management and quality of life among stroke survivors. The main question it aims to answer is: does nurse-led stroke transitional care program improve discharge preparedness, disease self-management and quality of life among stroke survivors? Participants are currently participating in nurse-led stroke transitional care program as part of their medical care. Stroke survivors and their caregivers will be followed for six months period to assess their transitional care quality and clinical outcome measures.",[89,27],"Stroke Acute","2025-12-21",{"date":92,"type":38},"2026-01-06",{"date":94,"type":38},"2025-08-01",{"date":96,"type":21},"2026-03-30",{"name":98,"class":45},"Shandong University",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100613443","comparative-effects-of-sensory-augmentation-and-neuromodulation-on-enhancing-motor-recovery-among-stroke-survivors-100613443","NCT07266662","Comparative Effects of Sensory Augmentation and Neuromodulation on Enhancing Motor Recovery Among Stroke Survivors","Inclusion Criteria:\n\n* Age: 45-65\n* Gender: both male and female\n* Ischemic stroke\n* Diagnosed cases of middle cerebral artery stroke by neurologist\n* Stage of recovery - Chronic (more than 6 months)\n* Burnstromm recovery stage 3\n* Good Compliance\n\nExclusion Criteria:\n\n* Vestibular Dysfunction\n* Serious cognitive impairment,\n* Severe vision or visuospatial neglect\n* Spasticity (Modified Ashworth scale \\>3)\n* Upper extremity contractures\n* Upper extremity fractures\n* Orthopedic disease\n* Neurological conditions (other than stroke)\n* Recurrence of stroke or epilepsy during the study period\n* Serious systemic impairment or concomitant diseases\n* Patients refused to participate in the experiment","45 Years","56 Years",{"count":108,"type":21},36,[24],"This study aims to evaluate the effectiveness of two rehabilitation techniques-Sensory Augmentation (using mirror therapy) and Neuromodulation (using transcranial direct current stimulation, tDCS)-in improving motor recovery among stroke survivors. Stroke often results in long-term impairments, particularly in upper limb motor function, which is critical for daily activities. Although current rehabilitation strategies help, more effective solutions are needed to enhance recovery. Participants, aged 45-65 with chronic stroke and upper extremity impairments, will be randomized into three groups: Group 1 will receive a combination of sensory augmentation (mirror therapy) and neuromodulation (tDCS) with routine physical therapy; Group 2 will receive sensory augmentation (mirror therapy) with routine physical therapy; and Group 3 will receive neuromodulation (tDCS) with routine physical therapy. The interventions will take place four times a week for 8 weeks, and participants will undergo motor function assessments, including the Fugl-Meyer Assessment and Jebsen-Taylor Test, before and after the intervention. The study will compare the effects of each intervention on motor recovery, specifically focusing on upper limb function and motor control. The findings could lead to improved rehabilitation protocols, offering stroke survivors better therapeutic options and enhancing their quality of life.",[27],[113,114,115,116,117,118,119,120],"neuromuscular rehabilitation","sensory augmentation","neuromodulation","motor recovery","upper limb function","neuroplasticity","Fugl-Meyer Assessment","Jebsen-Taylor Test","2025-12-16",{"date":123,"type":38},"2025-12-17",{"date":125,"type":38},"2025-11-25",{"date":127,"type":21},"2026-05-30",{"name":129,"class":45},"Lahore University of Biological and Applied Sciences",2,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":4},"100612637","coast-study---cholesterol-optimization-after-stroke-100612637","NCT07256171","COAST Study - Cholesterol Optimization After Stroke","Cholesterol Optimization After Stroke: a Multicenter Prospective Study on LDL Cholesterol Control in Patients With Acute Stroke.","COAST","Inclusion Criteria:\n\n* • Recent acute cerebrovascular event, defined as a confirmed diagnosis of ischemic stroke, hemorrhagic stroke, or TIA occurring less than 30 days prior to enrollment.\n\n  * Availability of a baseline measured LDL cholesterol value (direct or calculated) at the time of the index event or close to it.\n  * Patients for whom, in routine clinical practice, a lipid-lowering therapy has been indicated and prescribed for secondary prevention (low-fat diet, supplements, statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, fibrates, or other lipid-lowering agents).\n  * Written informed consent obtained and signed by the patient before inclusion. If the patient is unable to provide consent autonomously (e.g., due to aphasia, impaired consciousness, etc.), informed consent will be obtained from a legal representative or proxy, in accordance with applicable regulations.\n\nExclusion Criteria:\n\n* • Comorbidities or conditions preventing 3-month follow-up: e.g., terminal oncological disease with life expectancy \\\u003C3 months, severe cognitive impairment (e.g., advanced dementia), or other conditions that make it impossible to obtain follow-up information; inability to contact the patient after discharge (e.g., non-resident foreign patient or lacking telephone contacts).\n\n  * Any other clinical, psychological, or social condition that, in the investigator's judgment, may compromise the patient's ability to adhere to the study or the reliability of the collected data.",{"count":140,"type":21},500,"This study (acronym COAST Trial) is a multicenter observational registry aiming to document: patients' adherence and persistence to lipid-lowering therapy prescribed for secondary prevention; the proportion of patients achieving LDL cholesterol therapeutic targets at 3 months; the incidence of cerebrovascular recurrence and mortality at 90 days, as well as the occurrence of any adverse effects from these therapies. This information will provide a snapshot of post-stroke\u002FTIA lipid-lowering management across centers and identify areas for improvement, offering useful data to optimize secondary prevention strategies in everyday clinical practice.",[27,143],"Cerebral Hemorrhage",[145,146,147,148,149,150,151,152,153],"LDL cholesterol","lipid-lowering agents","statins","ezetimibe","bempedoic acid","PCSK9 inhibitors","stroke","cerebral hemorrhage","transient ischemic attack","2025-11-20",{"date":156,"type":38},"2025-12-01",{"date":158,"type":21},"2026-01-01",{"date":160,"type":21},"2026-12-31",{"name":162,"class":45},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":170,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":46},"100606350","phase-3-cilostazol-for-prevention-of-recurrent-stroke-trial-100606350","NCT07174414","Cilostazol for Prevention of Recurrent Stroke Trial","Clarity","Inclusion Criteria:\n\n* Diagnosis of stroke or mini-stroke (also called TIA) within the last 180 days\n* Currently taking aspirin or clopidogrel (not both) to prevent another stroke\n\nExclusion Criteria:\n\n* Had a spontaneous brain bleed within the last 2 years.\n* Moderate to severe heart failure.\n* Life expectancy is less than 6 months.","40 Years",{"count":172,"type":21},2000,[174],"PHASE3","The goal of this clinical trial is to learn whether adding cilostazol to aspirin or clopidogrel prevents stroke and heart attack in people who have had a stroke or mini-stroke.",[177,178,179,180,181,27,182],"Stroke Recurrence","Myocardial Infarction","Vascular Death","Ischemic Stroke","TIA (Transient Ischemic Attack)","Recurrent Stroke","2025-09-12",{"date":185,"type":38},"2025-09-16",{"date":187,"type":21},"2026-08",{"date":189,"type":21},"2031-07",{"name":191,"class":45},"Stanford University",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":46},"100601634","neuromodulation-enhanced-use-of-robotic-balance-training-to-improve-balance-function-in-individuals-with-stroke-100601634","NCT07113041","Neuromodulation-Enhanced Use of RObotic BALANCE Training to Improve Balance Function in Individuals With Stroke","NEUROBALANCE","Inclusion Criteria:\n\n1. Aged between 18-75 years\n2. Diagnosed with a cortical\u002Fsubcortical ischemic stroke at least 6 months before the screening, as confirmed by the neurological exam or an MRI.\n3. Have complaints of impaired balance and poor postural control determined by a BBS score of ≤50.\n4. Ability to stand upright with or without support for at least 20 seconds\n5. Ability to walk with or without a walking aid for at least ten meters\n6. Not planning to change medication in the next four months\n7. Minimum Cognitive Ability to understand the verbal instructions and comply with the study procedures, as determined by the University of California, San Diego, Brief Assessment of Capacity to Consent Instrument (UBACC).\n\nExclusion Criteria:\n\n1. Currently undergoing any regular physical therapy program or research studies focusing on balance functions.\n2. Having a brainstem stroke.\n3. Contraindication for MRI scan (presence of metal implants, claustrophobia)\n4. Affected by the peripheral nerve injury, neuromuscular conditions, or orthopedic issues of lower limbs before stroke, or have any persistent pain or difficulty maintaining blood pressure while upright.\n5. Have a scalp or skin condition (e.g., psoriasis or eczema) \\* on the scalp near the stimulation site\n6. Having severe visual impairment (e.g., spatial neglect) or hearing problems that may affect study compliance\n7. Any other neurological injury or psychiatric conditions (e.g., severe anxiety or schizophrenia etc.)\n8. Contraindications to MRI, including the presence of non-titanium metallic implants, claustrophobia, etc.\n9. Not be pregnant or thinking of becoming pregnant\n10. Diagnosed with alcohol or substance abuse in the last 3 years\n11. Contraindications to TMS, including the presence of metallic implants in the head and a history of seizures or medication-resistant epilepsy or ongoing use of anti-seizure\u002Fseizure threshold-lowering medications.","75 Years",{"count":201,"type":21},45,[24],"Our proposed study, \"NEUROBALANCE Stroke,\"; aims to evaluate the effectiveness of a combined intervention involving robotic balance training and noninvasive brain stimulation in improving balance function and postural control in individuals with chronic stroke. The study will recruit 45 participants who have had a stroke at least 6 months before enrolment and experience persistent balance and gait deficits. Participants will be randomized into three groups: (1) robotic balance training with active brain stimulation, (2) robotic balance training with sham brain stimulation, and (3) standard-of-care rehabilitation.\n\nThe study will involve 15 training sessions over 5 weeks, with assessments conducted at baseline, post-training, and two months post-training to evaluate balance recovery and retention. The primary focus is understanding how this intervention affects brain and muscle activity during balance tasks and how these changes translate into functional improvements in clinical outcome measures of balance function. Additionally, participant feedback on brain stimulation and exercise engagement will be collected to inform future studies.\n\nThe findings may guide the development of personalized training protocols and contribute to broader rehabilitation strategies.",[59,27,205,206,207],"Stroke Ischemic","Stroke Gait Rehabilitation","Balance Deficits",{"date":209,"type":38},"2025-08-08",{"date":211,"type":38},"2025-06-01",{"date":213,"type":21},"2029-08-31",{"name":215,"class":45},"Kessler Foundation",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":16,"minAge":170,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":236,"locationsCount":46},"100499257","phase-4-effects-of-semaglutide-on-intracranial-blood-flow-and-brain-barrier-permeability-in-type-2-diabetes-100499257","NCT05780905","Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes","Inclusion Criteria:\n\n1. Men and women 40-65 years of age\n2. Subjects with type-2 diabetes \\>= 3 years and HbA1C 7%-10% with blood sugar control medications including insulin, metformin, sulfonylureas, or SGLT2 inhibitors\n3. Medically stable\n4. Has not received any investigational drug in the past 6 months\n5. Willing to participate and sign informed consent.\n\nExclusion Criteria:\n\n1. Contraindication to MRI or contrast agent\n2. eGFR\\\u003C45 mL\u002Fmin\u002F1.73m2 (eGFR is a measurement of kidney function)\n3. Currently treated with glucagon-like peptide-1 receptor antagonist (same drug class as study intervention)\n4. Unable to perform home-glucose monitoring\n5. Currently need more than 100 units of insulin daily\n6. Uncontrolled hypertension with systolic blood pressure (SBP)\\>180 mmHg or diastolic blood pressure (DBP)\\>100 mmHg\n7. LDL-C\\>130 mg\u002FdL or not on stable statin therapy in the past 6 months\n8. Treatment with pioglitazone in the past 3 months\n9. History of pancreatitis\n10. History of myocardial infarction, stroke or transient ischemic attack\n11. History or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)\n12. Hypersensitivity to semaglutide or any of the product components\n13. Participating in other clinical trial\n14. Women of child-bearing potential (ie, those who are not chemically or surgically sterilized or who are not post-menopausal) who have a positive pregnancy test at enrollment or who are breastfeeding or who plan to become pregnant in the next 15 months.","65 Years",{"count":224,"type":21},50,[226],"PHASE4","A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with diabetes to either semaglutide or matching placebo. Magnetic resonance images will be primary endpoint measured at baseline and at one year to assess effect of this FDA approved medication.\n\nGiven the available evidence supporting the neuroprotective effect of this drug class and stroke reduction with semaglutide, and the investigators preliminary data showing that T2D had significantly reduced total number of distal arterial branches in the brain than non-T2D, the investigators expect treatment with semaglutide will be associated with improved intracranial blood flow condition.",[229,27],"Diabetes Mellitus, Type 2","2024-06-04",{"date":232,"type":38},"2024-06-05",{"date":234,"type":38},"2024-01-11",{"date":160,"type":21},{"name":237,"class":45},"University of Washington"]